Antimicrobial Drug Resistance

1. Front Matter

   Pages i-xxi

   PDF

2. General Overview

   1. Front Matter

      Pages 1-1

      PDF

   2. History of Drug-Resistant Microbes

      • George A. Jacoby

      Pages 3-8

   3. Evolutionary Biology of Drug Resistance

      • Fernando Baquero, Rafael Cantón

      Pages 9-36

   4. Pharmacology of Drug Resistance

      • Elizabeth R. Andrews, Angela D. M. Kashuba

      Pages 37-43

   5. Drug Development for Drug-Resistant Pathogens

      • Jacques Dumas, Michael J. Pucci, Greg Moeck

      Pages 45-57

3. General Mechanisms of Drug Resistance

   1. Front Matter

      Pages 59-59

      PDF

   2. Genetic Mechanisms of Transfer of Drug Resistance

      • Paul H. Roy, Sally R. Partridge

      Pages 61-76

   3. Mutations as a Basis of Antimicrobial Resistance

      • Robert A. Bonomo

      Pages 77-87

   4. Target-Mediated Antibacterial Resistance

      • Liza Valdivia, Louis B. Rice

      Pages 89-95

   5. Biochemical Logic of Antibiotic Inactivation and Modification

      • Vanessa M. D’Costa, Gerard D. Wright

      Pages 97-113

   6. Antibiotic Resistance due to Reduced Uptake

      • Lucía Fernández, Joseph B. McPhee, Sandeep Tamber, Michelle D. Brazas, Shawn Lewenza, Robert E. W. Hancock

      Pages 115-130

   7. Active Efflux as a Mechanism of Resistance to Antimicrobial Drugs

      • Xian-Zhi Li

      Pages 131-148

   8. The Functional Resistance of Biofilms

      • Elias K. Manavathu, Jose A. Vazquez

      Pages 149-162

4. Bacterial Drug Resistance: Mechanisms

   1. Front Matter

      Pages 163-163

      PDF

   2. The Importance of β-Lactamases to the Development of New β-Lactams

      • Karen Bush

      Pages 165-175

   3. Penicillin-Binding Proteins and β-Lactam Resistance

      • André Zapun, Pauline Macheboeuf, Thierry Vernet

      Pages 177-211

   4. Aminoglycosides: Mechanisms of Action and Resistance

      • Alisa W. Serio, Maria L. Magalhães, John S. Blanchard, Lynn E. Connolly

      Pages 213-229

   5. Tetracycline and Chloramphenicol Resistance Mechanisms

      • Marilyn C. Roberts, Stefan Schwarz

      Pages 231-243

   6. Fluoroquinolone Resistance in Bacteria

      • Bryan D. Schindler, Joseph Adrian L. Buensalido, Glenn W. Kaatz

      Pages 245-263

The two volumes included in Antimicrobial Drug Resistance, Second Edition is an updated, comprehensive and multidisciplinary reference covering the area of antimicrobial drug resistance in bacteria, fungi, viruses, and parasites from basic science, clinical, and epidemiological perspectives. This newly revised compendium reviews the most current research and development on drug resistance while still providing the information in the accessible format of the first edition. The first volume, Antimicrobial Drug Resistance: Mechanisms of Drug Resistance, is dedicated to the biological basis of drug resistance and effective avenues for drug development. With the emergence of more drug-resistant organisms, the approach to dealing with the drug resistance problem must include the research of different aspects of the mechanisms of bacterial resistance and the dissemination of resistance genes as well as research utilizing new genomic information. These approaches will permit the design of novel strategies to develop new antibiotics and preserve the effectiveness of those currently available. The second volume, Antimicrobial Drug Resistance: Clinical and Epidemiological Aspects, is devoted to the clinical aspects of drug resistance. Although there is evidence that restricted use of a specific antibiotic can be followed by a decrease in drug resistance to that agent, drug resistance control is not easily achieved. Thus, the infectious diseases physician requires input from the clinical microbiologist, antimicrobial stewardship personnel, and infection control specialist to make informed choices for the effective management of various strains of drug-resistant pathogens in individual patients. This 2-volume set is an important reference for students in microbiology, infectious diseases physicians, medical students, basic scientists, drug development researchers, microbiologists, epidemiologists, and public health practitioners.

• antibiotics
• antivirals
• drug resistance
• infectious disease
• bacteria
• pathogen
• antifungal
• antibacterial drug resistance
• infectious diseases

• Treiber Therapeutics, Cambridge, USA

  Douglas L. Mayers

• Wayne State University School of Medicine, Detroit Medical Center, Detroit, USA

  Jack D. Sobel

• Centre de recherche en Infectiologie, University of Laval, Quebec City, Canada

  Marc Ouellette

• Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, USA

  Keith S. Kaye

• Infection Control and Prevention Unit of Infectious Diseases, Assaf Harofeh Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel

  Dror Marchaim

Douglas L. Mayers is an infectious diseases specialist and is currently Chief Medical Officer (CMO) at Cocrystal Pharma. Dr. Mayers received his M.D. from University of Pennsylvania and has over 20 years of medical and clinical development experience spanning all phases of global clinical research and development and commercialization. He has worked with the United States Army Medical Research Institute of Infectious Diseases to discover and develop drugs against the Ebola virus. He has also served as the Head of HIV Clinical Studies Program and Department of HIV Disease Prevention at the Walter Reed Army Institute of Research and Naval Medical Research Institute. Previously, he was the Chief Medical Officer and Executive Vice President at Idenix Pharmaceuticals, where he directed the Infectious Disease programs and led numerous regulatory filings globally, including successful advancement of several anti-HCV candidates to the clinical phase. Prior to Idenix, he was the International Head/Vice President of the Virology Therapeutic Area at Boehringer Ingelheim where he led Phase 1 through 4 clinical studies for HIV and hepatitis programs. In addition to his extensive expertise in the industry and in research, Dr. Mayers is well-known in the academic sphere and is the author of over 95 peer-reviewed publications and book chapters.

Policies and ethics